Cantor picks 14 undervalued biotech stocks worth a second look
Seeking Alpha News (Sun, 12-May 11:00 AM ET)
Alnylam Issues 2023 Corporate Responsibility Report
Business Wire (Tue, 7-May 8:00 AM ET)
Business Wire (Thu, 2-May 8:00 AM ET)
PRNewswire (Tue, 30-Apr 7:00 AM ET)
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
Business Wire (Thu, 18-Apr 8:00 AM ET)
Business Wire (Sun, 7-Apr 8:00 AM ET)
Business Wire (Wed, 20-Mar 8:00 AM ET)
Business Wire (Wed, 13-Mar 7:30 AM ET)
PRNewswire (Mon, 11-Mar 7:30 PM ET)
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Alnylam Pharmaceuticals trades on the NASDAQ stock market under the symbol ALNY.
As of May 13, 2024, ALNY stock price climbed to $150.93 with 229,116 million shares trading.
ALNY has a beta of 1.30, meaning it tends to be more sensitive to market movements. ALNY has a correlation of 0.24 to the broad based SPY ETF.
ALNY has a market cap of $19.01 billion. This is considered a Large Cap stock.
Last quarter Alnylam Pharmaceuticals reported $494 million in Revenue and -$.16 earnings per share. This beat revenue expectation by $67 million and exceeded earnings estimates by $1.02.
In the last 3 years, ALNY stock traded as high as $242.97 and as low as $117.58.
The top ETF exchange traded funds that ALNY belongs to (by Net Assets): VTI, VO, VXF, VUG, VOT.
ALNY has underperformed the market in the last year with a return of -28.5%, while the SPY ETF gained +27.7%. In the last 3 month period, ALNY fell short of the market, returning -11.2%, while SPY returned +4.2%. However, in the most recent 2 weeks ALNY has outperformed the stock market by returning +5.3%, while SPY returned +2.4%.
ALNY support price is $148.06 and resistance is $152.88 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALNY stock will trade within this expected range on the day.